Zusammenfassung
Die stetige Zunahme an bakteriellen Resistenzen und von multiresistenten Erregern
(MRE) – vor allem im gramnegativen Bereich – ist ein weltweites Problem. Die Entwicklung
neuer Wirkstoffe gegen Infektionen mit multiresistenten gramnegativen Erregern (MRGN)
besitzt daher höchste Priorität. Im Folgenden werden kürzlich zugelassene oder in
der fortgeschrittenen klinischen Prüfung befindliche Antibiotika mit Wirksamkeit gegen
MRGN vorgestellt.
Abstract
New β-lactam/β-lactamase inhibitor (BLI) combinations (ceftolozan/tazobactam, ceftazidim/avibactam,
meropenem/vaborbactam, imipenem/relebactam, aztreonam/avibactam) are the focus of
newly approved antibiotics or those currently in advanced clinical testing. In contrast
to the BLI currently available, the new inhibitors avibactam, vaborbactam and relebactam
are not structurally β-lactams.
The combination with a BLI protects β-lactam from degradation by broad-spectrum β-lactamases
from gram-negative pathogens. The main indications for the new substances are therefore
infections with multi-resistant gram-negative bacteria.
In clinical use, it should be noted that the BLI does not close efficacy gaps in the
β-lactam/BLI combination (e.g. no effect of cephalosporin/BLI combinations on anaerobes
or enterococci).
Cefiderocol is the first representative of the siderophore cephalosporin antibiotic
group to enter phase II clinical testing.
Eravacyclin (tetracycline derivative) and plazomicin (aminoglycoside) are new non-β-lactam
antibiotics in advanced clinical testing (phase III).
In order to maintain the efficacy of new reserve antibiotics for as long as possible,
a prescription should only be made if an additional benefit in comparison to established
substances has been proven, e.g. by a resistance test.
Schlüsselwörter
Antibiotika - multiresistente gramnegative Bakterien - β-Laktam-Antibiotika - β-Laktamase-Inhibitoren
Key words
antibiotics - highly resistant gram-negative bacteria - beta-lactam antibiotics -
beta-lactamase inhibitors
